South Korea · Delayed Price · Currency is KRW Access Bio Statistics
Total Valuation
Access Bio has a market cap or net worth of KRW 91.28 billion. The enterprise value is -240.30 billion.
| Market Cap | 91.28B |
| Enterprise Value | -240.30B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Access Bio has 35.17 million shares outstanding. The number of shares has increased by 38.67% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 35.17M |
| Shares Change (YoY) | +38.67% |
| Shares Change (QoQ) | -3.65% |
| Owned by Insiders (%) | 0.44% |
| Owned by Institutions (%) | 0.30% |
| Float | 25.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.11 |
| PB Ratio | 0.16 |
| P/TBV Ratio | 0.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.86, with a Debt / Equity ratio of 0.08.
| Current Ratio | 16.86 |
| Quick Ratio | 15.31 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.61 |
| Interest Coverage | -33.04 |
Financial Efficiency
Return on equity (ROE) is -13.81% and return on invested capital (ROIC) is -30.78%.
| Return on Equity (ROE) | -13.81% |
| Return on Assets (ROA) | -6.27% |
| Return on Invested Capital (ROIC) | -30.78% |
| Return on Capital Employed (ROCE) | -11.27% |
| Weighted Average Cost of Capital (WACC) | 4.86% |
| Revenue Per Employee | 147.91M |
| Profits Per Employee | -823.45M |
| Employee Count | 101 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 3.21 |
Taxes
| Income Tax | -24.73B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.26% in the last 52 weeks. The beta is 0.21, so Access Bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | -56.26% |
| 50-Day Moving Average | 3,164.00 |
| 200-Day Moving Average | 3,806.85 |
| Relative Strength Index (RSI) | 33.86 |
| Average Volume (20 Days) | 1,149,333 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Access Bio had revenue of KRW 14.94 billion and -83.17 billion in losses. Loss per share was -2,364.02.
| Revenue | 14.94B |
| Gross Profit | -33.68B |
| Operating Income | -67.24B |
| Pretax Income | -108.77B |
| Net Income | -83.17B |
| EBITDA | -52.74B |
| EBIT | -67.24B |
| Loss Per Share | -2,364.02 |
Balance Sheet
The company has 376.46 billion in cash and 43.70 billion in debt, with a net cash position of 332.76 billion or 9,460.33 per share.
| Cash & Cash Equivalents | 376.46B |
| Total Debt | 43.70B |
| Net Cash | 332.76B |
| Net Cash Per Share | 9,460.33 |
| Equity (Book Value) | 571.29B |
| Book Value Per Share | 16,445.62 |
| Working Capital | 395.69B |
Cash Flow
In the last 12 months, operating cash flow was -70.60 billion and capital expenditures -984.22 million, giving a free cash flow of -71.59 billion.
| Operating Cash Flow | -70.60B |
| Capital Expenditures | -984.22M |
| Depreciation & Amortization | 14.50B |
| Net Borrowing | -3.98B |
| Free Cash Flow | -71.59B |
| FCF Per Share | -2,035.24 |
Margins
| Gross Margin | -225.45% |
| Operating Margin | -450.09% |
| Pretax Margin | -728.08% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Access Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.67% |
| Shareholder Yield | -38.67% |
| Earnings Yield | -91.12% |
| FCF Yield | -78.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Access Bio has an Altman Z-Score of 3.55 and a Piotroski F-Score of 2.
| Altman Z-Score | 3.55 |
| Piotroski F-Score | 2 |